Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 74% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work and whether you can afford to take the high risk of losing your money.

English

Regional settings

Entity•Capital Com UK LimitedAuthorised and regulated by the Financial Conduct Authority (FCA)

My account

Home Markets SharesALPS Medical Breakthroughs ETF

Trade ALPS Medical Breakthroughs ETF - SBIO CFD

Summary Historical Data

Trading Conditions

Spread

0.17

Long position overnight fee

Long position overnight fee

Margin. Your investment	$1,000.00
Overnight fee Charges from full value of position	-0.026179 % (-$1.05)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

Go to platform

-0.026179%

Short position overnight fee

Short position overnight fee

Margin. Your investment	$1,000.00
Overnight fee Charges from full value of position	0.003957 % ($0.16)

Trade size with leverage ~ $5,000.00

Short position overnight fee ~ $4,000.00

Go to platform

0.003957%

Overnight fee time

21:00 (UTC)

Currency

USD

Min traded quantity

Margin

Stock exchange

United States of America

Commission on trade¹

¹Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats

Prev. Close	32.86
Open	32.54
1-Year Change	8.83%
Day's Range	32.54 - 33

ALPS Medical Breakthroughs ETF Company profile

The investment seeks investment results that correspond (before fees and expenses) generally to the performance of its underlying index, the S-Network® Medical Breakthroughs Index. The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.